Expression of Circadian Clock Gene Human Period2 (hPer2) in Human Colorectal Carcinoma

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2011 Dec 15

PMID 22166120

Citations 21

Authors

Yaping Wang

Luchun Hua

Chao Lu

Zongyou Chen

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies have shown that disruption of circadian rhythms is one of the tumor promoting factors which contribute to mammalian cancer development and progression, but very little is known about the molecular changes of circadian genes in colorectal carcinoma (CRC). Thus, in this study, changes in the expression of human Period2 (hPer2), one of the key circadian clock regulators, in CRC and its correlation with prognosis were investigated.

Methods: Immunohistochemical (IHC) staining and real-time PCR for hPer2 were performed for 38 CRC cases.

Results: IHC analysis detected positive staining for hPer2 in 81.6% (31/38) of CRC tissues and 97.4% (37/38) of surrounding non-cancerous tissues (P < 0.05). Most colorectal cells in non-cancerous tissues were homogeneously stained. In contrast, in the paired cancerous tissues, a heterogeneous pattern was found with a significant portion of cancer cells displaying negative or weak hPer2 staining. In over 60% cases (24/38), the staining for hPer2 was much stronger in non-cancerous cells than in the paired cancerous cells. Well-differentiated cancer cells are more likely to maintain hPer2 expression than poorly-differentiated ones. Furthermore, associations of decreased hPer2 levels with patients' age, histological grade, TNM stage and expression of nucleus proliferation related antigen: Ki67 were also detected (P < 0.05). Expression of hPer2 did not correlate with that of either p53 or C-erB-2. Similar to hPer2 protein expression, quantitative RT-PCR for hPer2 also showed decreased mRNA expression in CRC.

Conclusion: These results suggest a role for hPer2 in normal colorectal cell function and the potential deregulation of hPer2 expression in the development, invasion, and metastasis of CRC.

Citing Articles

Clock gene Per2 modulates epidermal tissue repair in vivo.

Yujra V, da Silveira E, Ribeiro D, Castilho R, Squarize C J Cell Biochem. 2024; 125(2):e30513.

PMID: 38229522 PMC: 10932909. DOI: 10.1002/jcb.30513.

Circadian clock as a possible control point in colorectal cancer progression (Review).

Rao X, Lin L Int J Oncol. 2022; 61(6).

PMID: 36263655 PMC: 9591320. DOI: 10.3892/ijo.2022.5439.

Advances in the Study of Circadian Genes in Non-Small Cell Lung Cancer.

Zhang H, Liu R, Zhang B, Huo H, Song Z Integr Cancer Ther. 2022; 21:15347354221096080.

PMID: 35575281 PMC: 9121494. DOI: 10.1177/15347354221096080.

Genome-wide analysis of cell-Free DNA methylation profiling with MeDIP-seq identified potential biomarkers for colorectal cancer.

Zhang X, Li T, Niu Q, Qin C, Zhang M, Wu G World J Surg Oncol. 2022; 20(1):21.

PMID: 35065650 PMC: 8783473. DOI: 10.1186/s12957-022-02487-4.

Low circadian clock genes expression in cancers: A meta-analysis of its association with clinicopathological features and prognosis.

Zhang J, Lv H, Ji M, Wang Z, Wu W PLoS One. 2020; 15(5):e0233508.

PMID: 32437452 PMC: 7241715. DOI: 10.1371/journal.pone.0233508.

References

Lee C . Tumor suppression by the mammalian Period genes. Cancer Causes Control. 2006; 17(4):525-30. DOI: 10.1007/s10552-005-9003-8. View

Chen S, Choo K, Hou M, Yeh K, Kuo S, Chang J . Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005; 26(7):1241-6. DOI: 10.1093/carcin/bgi075. View

Canaple L, Kakizawa T, Laudet V . The days and nights of cancer cells. Cancer Res. 2003; 63(22):7545-52. View

Bjarnason G, Jordan R, Wood P, Li Q, Lincoln D, Sothern R . Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol. 2001; 158(5):1793-801. PMC: 1891949. DOI: 10.1016/S0002-9440(10)64135-1. View

Gery S, Koeffler H . The role of circadian regulation in cancer. Cold Spring Harb Symp Quant Biol. 2008; 72:459-64. DOI: 10.1101/sqb.2007.72.004. View

Block K, Block P, Fox S, Birris J, Feng A, de la Torre M . Making circadian cancer therapy practical. Integr Cancer Ther. 2010; 8(4):371-86. DOI: 10.1177/1534735409352028. View

Gery S, Gombart A, Yi W, Koeffler C, Hofmann W, Koeffler H . Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood. 2005; 106(8):2827-36. PMC: 1895299. DOI: 10.1182/blood-2005-01-0358. View

Scheving L . Biological clocks and the digestive system. Gastroenterology. 2000; 119(2):536-49. DOI: 10.1053/gast.2000.9305. View

Hua H, Wang Y, Wan C, Liu Y, Zhu B, Wang X . Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther. 2007; 14(9):815-8. DOI: 10.1038/sj.cgt.7701061. View

10.

Zhang E, Liu A, Hirota T, Miraglia L, Welch G, Pongsawakul P . A genome-wide RNAi screen for modifiers of the circadian clock in human cells. Cell. 2009; 139(1):199-210. PMC: 2777987. DOI: 10.1016/j.cell.2009.08.031. View

11.

Yang X, Wood P, Oh E, Du-Quiton J, Ansell C, Hrushesky W . Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat. 2008; 117(2):423-31. DOI: 10.1007/s10549-008-0133-z. View

12.

Zheng B, Larkin D, Albrecht U, Sun Z, Sage M, Eichele G . The mPer2 gene encodes a functional component of the mammalian circadian clock. Nature. 1999; 400(6740):169-73. DOI: 10.1038/22118. View

13.

Innominato P, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J . Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009; 69(11):4700-7. PMC: 2690615. DOI: 10.1158/0008-5472.CAN-08-4747. View

14.

Giacchetti S . Chronotherapy of colorectal cancer. Chronobiol Int. 2002; 19(1):207-19. DOI: 10.1081/cbi-120002602. View

15.

Ko C, Takahashi J . Molecular components of the mammalian circadian clock. Hum Mol Genet. 2006; 15 Spec No 2:R271-7. DOI: 10.1093/hmg/ddl207. View

16.

Chen-Goodspeed M, Lee C . Tumor suppression and circadian function. J Biol Rhythms. 2007; 22(4):291-8. DOI: 10.1177/0748730407303387. View

17.

Gery S, Virk R, Chumakov K, Yu A, Koeffler H . The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 2007; 26(57):7916-20. DOI: 10.1038/sj.onc.1210585. View

18.

Yang X, Wood P, Ansell C, Hrushesky W . Circadian time-dependent tumor suppressor function of period genes. Integr Cancer Ther. 2009; 8(4):309-16. DOI: 10.1177/1534735409352083. View

19.

Filipski E, King V, Li X, Granda T, Mormont M, Liu X . Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002; 94(9):690-7. DOI: 10.1093/jnci/94.9.690. View

20.

Toh K, Jones C, He Y, Eide E, Hinz W, Virshup D . An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science. 2001; 291(5506):1040-3. DOI: 10.1126/science.1057499. View